Terazosin And Metabolic Engagement in Alzheimer's Disease
Qiang Zhang
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The TAME-AD trial will be a randomized, double-blind, placebo-controlled Phase IIa clinical trial to evaluate the metabolic target engagement of terazosin for the treatment of Alzheimer's disease.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- acronym
- TAME-AD
- status
- NOT_YET_RECRUITING
- phase
- PHASE2
- study type
- INTERVENTIONAL
- enrollment
- 100
- sponsor
- Qiang Zhang
- conditions
- Alzheimer s Disease
- interventions
- DRUG: Terazosin (Hytrin); OTHER: Placebo
- start date
- 2027-08-01
- start date type
- ESTIMATED
- primary completion date
- 2031-07-31
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT07796308
- Published
- Sep 1, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT07796308
- Categories
- Alzheimer s Disease
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials